morphism. In contrast, Canli and Lesch 6 studying 41 healthy controls (L'L = 13, S' = 28) found widespread reductions in gray matter in S' carriers (insula, left middle frontal gyrus and gyrus rectus, right inferior temporal gyrus, anterior cingulate and cerebellum). Frodl et al., 7 using the trialleleic polymorphism in 77 healthy controls, also found rather more widespread reductions in gray matter in S' carriers (left amygdala, right hippocampus, left anterior cingulate cortex and bilateral dorsolateral prefrontal cortex). However, in the latter study, the morphometric comparisons appear to have been restricted to L'L' (n = 10) and S'S' (n = 23) homozygotes. Finally, a recent study in non-human primates 3 (4 L'L' vs 4 L'S') reported widespread reductions in gray matter volume in S' carriers including anterior cingulate, medial prefrontal and orbitofrontal cortex as well as the amygdala.
Taken together, the studies suggest that carriage of the S' allele may influence brain function through an effect on brain morphology, perhaps exerted during neurodevelopment. Larger samples appear to have more restricted morphological changes; however, an effect of S' carriage on anterior cingulate volume appears a reliable finding between different studies. This is of interest in view of the role of the anterior cingulate in integrating cognitive and emotional information as well as its frequent implication in functional imaging studies in depressed patients. Diacylglycerol kinase eta (DGKH) was the first bipolar disorder (BPD) susceptibility gene identified by genome-wide association study. 1 It is located on 13q14, a region having shown some linkage evidence for BPD and schizophrenia (SCZ).
2 DGKH encodes an important protein in the lithium-sensitive phosphatidyl inositol signaling pathway. A number of studies have been conducted in different European populations to replicate the association between DGKH and BPD. Although one study found positive haplotypic association in a Sardinian sample, 3 all the others reported negative results. [4] [5] [6] However, our preliminary meta-analysis (data not shown) indicated that the association of the three single-nucleotide polymorphisms (SNPs) (rs9315885, rs1012053 and rs1170191) found in all these studies, as well as in Welcome Trust Case Control Consortium (WTCCC) imputed data was all in the same direction. For further study of the possible role of DGKH in the pathogenesis of major psychiatric disorders and considering the genetic etiology overlap of BPD, SCZ and major depressive disorder, we carried out large-scale casecontrol studies to test the association between DGKH and these three disorders in the Chinese Han population.
Our sample sets consisted of 1139 unrelated BPD patients (645 type I BPD), 1122 unrelated SCZ patients, 1122 unrelated major depressive disorder patients and 1138 shared healthy controls. All subjects were of Chinese Han origin. Taqman assay was used to genotype 13 tag SNPs, including the three broadly replicated SNPs (rs9315885, rs1012053 and rs1170191). Main association analyses were performed on Haploview 4.1. 7 Only haplotypes with an estimated frequency > 3% were evaluated. 10 000 permutations were carried out to correct the multiple tests. The statistical power to detect a significant association at ap0.05 was above 85% in each single-site comparison and above 70% in the haplotype analyses, with a medium effect size (odds ratio (OR) = 1.5). No severe deviations from HardyWeinberg equilibrium in controls were found.
After permutation, one SNP rs2122246 located in the 3 0 -flank region of DGKH showed significant association in the type I BPD subgroup (OR = 0.799, 95% confidence interval (CI) = 0.693-0.921), and another SNP rs1170099 in the 3 0 -flank region was strongly associated with SCZ (OR = 1.612, 95% CI = 1.231-2.112).
We identified three haplotype blocks according to the pairwise linkage disequilibrium (Supplementary Figure 1) . No single SNP was associated with BPD in block1, but the block showed strong association as a haplotype. C-A-C acted as a protective haplotype (OR = 0.836, 95% CI = 0.743-0.939), whereas C-A-A was identified as a risk haplotype (OR = 1.975, 95% Abbreviations: BPD, bipolar disorder; type I BPD, type I bipolar disorder; permP, permutated P; SCZ, schizophrenia; SNP, single-nucleotide polymorphism. Block1: rs9315885-rs9532988-rs1012053; Block2: rs716934-rs9566931-rs9315897-rs2122246; Block3: rs1170099-rs9566940. Significant permP values ( < 0.05) are in bold. CI = 1.472-2.649). When cases were confined to type I BPD, we generated similar results and also found a significantly associated haplotype T-A-T-A (OR = 0.816, 95% CI = 0.709-0.939) in block2. Block1 and block3 were associated with SCZ. Unlike the situation in BPD, the associated haplotype in block1 was T-A-A (OR = 0.804, 95% CI = 0.711-0.909). In block3, the associated haplotype was G-T (OR = 0.6, 95% CI = 0.458-0.785).
Results for major depressive disorder were totally negative. There was no nominally significant allelic or haplotypic association in any of the analyses (data not shown). Details of allelic and haplotypic association results for BPD and SCZ are shown in Table 1 .
Potential population stratification in our samples was analyzed using 68 additional random SNPs dispersed on different chromosomes. The analysis was performed on STRUCTURE 2.3.1. 8 We did not detect any population stratification, and therefore, the results could not be affected by this confounding factor (Supplementary Table 1 and Supplementary  Figure 2) .
Although we failed to replicate the strong association of the three SNPs for BPD found in the Baum study, 1 difference of the allele frequencies between our cases and controls had the same trends as those in theirs. After adding our data to that of other studies to conduct a meta-analysis (data not shown), we found that apart from one study on one SNP (rs1012053), 6 all replication studies [3] [4] [5] and the WTCCC imputed genome-wide association study data on the three SNPs indicated that the associated alleles were the same. As several other genome-wide association study have been conducted on BPD, it was of particular interest to perform a comprehensive metaanalysis to examine the combined effects.
The haplotype analyses provide further support for the involvement of DGKH in the risk of BPD. The most significantly associated haplotypes are located in the first intron of the DGKH gene, which is in accordance with the findings of Baum et al. that the strongest markers are in the first intron of the gene.
Our study is the first to show association between DGKH and SCZ. The associated SNP and haplotypes were distinct from those for BPD, which may be due to the inconsistency of the nosogenetic variants. Recently, a genome-wide analysis of genome-wide association study data sets presented evidence that DGKI (diacylglycerol kinase iota), a member of the diacylglycerol kinase (DGK) enzyme family, conferred risk of SCZ. 9 As a key protein in the lithium-sensitive signaling pathways, DGKH is predicted to have a role in lithium response and hence in mood control. However, the involvement of DGKH in lithium response has not yet been validated. Only one small study of 199 Sardinian subjects 10 has investigated the relationship between DGKH and lithium response and it was found to be negative. In summary, our results support DGKH as shared risk factor of BPD and SCZ in the Chinese Han population. For further understanding of the role of DGKH, a large-scale study of the relation between DGKH and lithium response is warranted.
